Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended): A method for the treatment of a postlesional disease of ischemic, traumatic or toxic origin characterized by nerve cell necrosis, comprising administering an effective amount of a compound of formula (I) to a human patient in need thereof:



(I)

wherein X represents ~~OH, (C_{1-5}) alkoxy,~~ NH_2, ~~NH-C_{1-5} alkyl, or N(C_{1-5} alkyl)$_2$~~ NH-(C_{1-3})alkyl or N(C_{1-3}alkyl)$_2$;

R_1 is a residue derived from ~~any of~~ the amino acid[[s]] Phe~~, Tyr, Trp, Pro, each of~~ which may optionally be substituted with one or more methoxy groups, or methyl groups ~~by a (C_{1-5}) alkoxy groups, a (C_{1-5}) alkyl group~~ or one or more halogen atoms, ~~and Ala, Val, Leu,~~ ; or is derived from the amino acid Ile;

R_2 is a residue which is derived from any one of the amino acids Gly~~, Ala,~~ or Ile~~, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu or Asn~~;

R_3-and R_4 independently represent ~~H, OH, (C_{1-5}) alkyl, or (C_{1-5}) alkoxy, provided that R_3 and R_4 are not both OH or (C_{1-5}) alkoxy;~~

R_5 represents ~~H, OH, (C_{1-5}) alkyl or (C_{1-5}) alkoxy~~;

and wherein R_0 represents a group of the formula



wherein Y represents -CO-, -CH_2CO-, ~~-CH_2CH_2CO-~~, ~~-$CH_2CH_2CH_2$CO-~~, -CH=CH-CO or -OCH_2CO-, and wherein Z represents a halogen atom, a trifluormethyl group, a methoxy group, a methyl group~~(C_{1-4}) alkoxy group, (C_{1-4}) alkyl group~~; or wherein two neighbouring substituents may form a (C_{1-3}) alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5;
or pharmaceutically acceptable salts thereof;

or a pharmaceutically acceptable salt thereof.

2. (Canceled)

3. (Currently Amended) The method according to claim 2, wherein R1 is a residue derived from Phe which may optionally be substituted by with one or more methoxy groups, or methyl groups ~~a (C_{1-5}) alkoxy groups, a (C_{1-5}) alkyl group~~ or ~~a~~ one or more halogen atoms.

4. (Canceled)

5. (canceled)

6. (previously presented): The method according to claim 1, wherein R_0 is a cinnamoyl moiety.

7. (previously presented): The method according to claim 1, wherein the compound of formula (I) is cinnamoyl-glycyl-L-phenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.